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Abstract: The hyperphosphorylation and proteolytic modification of the TAR DNA binding protein-43 (TDP-43) is a 
key finding in a number of neurodegenerative diseases including frontotemporal dementia with ubiquitin-positive 
inclusions (FTLD-U), amyotrophic lateral sclerosis (ALS), and most recently Alzheimer’s disease (AD). To examine 
whether proteolytic modifications of TDP-43 is a relevant finding in Pick’s disease, we utilized a novel site-directed 
caspase-cleavage antibody based upon a known caspase-3 cleavage consensus site within TDP-43 at position 
219. Application of this antibody, termed TDP caspase-cleavage product (TDPccp) to postmortem Pick’s disease 
brain sections revealed the presence of caspase-cleaved TDP-43 in Pick and Hirano bodies predominantly within 
region CA1 of the hippocampus. Co-localization of TDPccp with PHF-1, a general marker for Pick bodies, as well as 
with an antibody to caspase-cleaved tau (TauC3) was evident within the hippocampus. A semi-quantitative 
analysis indicated that approximately 21% and 79% of the Pick bodies identified in area CA1 contained caspase-
cleaved TDP-43 or caspase-cleaved tau, respectively. Of interest was the lack of co-localization of TDPccp with 
PHF-1 in Pick bodies within the dentate gyrus. Collectively, these data have identified modified TDP-43 as a 
component of Pick and Hirano bodies that is restricted to area CA1 in Pick’s disease. The relative paucity of 
caspase-cleaved TDP-43 found within Pick bodies in comparison to caspase-cleaved tau suggests that TDP-43 
and its modification by caspases is most likely not a contributing factor leading to Pick body formation. 
 
Key Words: Pick’s disease, Pick bodies, caspases, TDP-43, Hirano bodies, tau
 
 
 
 
Introduction 
 
TAR DNA binding protein-43 (TDP-43) 
inclusions have recently been identified as a 
major feature of several neurodegenerative 
disorders including frontotemporal lobar 
degeneration with ubiquitin-positive inclusions 
(FTLD-U) and amyotrophic lateral sclerosis 
(ALS), [1]. A conspicuous finding in these 
studies was the presence of 25 and 35 kDa 
truncated fragments of TDP-43 in brain 
extracts from affected individuals that were 
not present in control subjects [1,2]. A similar 
25 kDa, truncated fragment of TDP-43 has 
also been identified in the Alzheimer’s disease 
(AD) brain [3]. Thus, post-translational 
proteolytic processing of TDP-43 may be a key 
step in protein misfolding and aggregation of 
TDP-43 leading to a toxic gain of function [4]. 
Recently, it has been determined that 
caspase-3 may be the protease involved in 
processing TDP-43 mediated through an 
interaction with progranulin [2]. These authors 
demonstrated that altered cleavage of TDP-43 
in cell culture models led to the production of 
25 kDa fragments of TDP-43 that were similar 
in appearance to those found in FTLD-U and 
ALS [2]. Therefore, abnormal turnover of TDP-
43 may underlie the neurodegeneration 
observed in these disorders. 
 
We recently developed a site-directed caspase-
cleavage antibody to TDP-43, which we termed 
TDPccp, and application of this antibody to 
postmortem AD brain sections labeled tangles, 
plaques, reactive astrocytes and Hirano bodies 
[5]. The purpose of the present study was to 
determine a possible role for caspase-cleaved 
TDP-43 in an additional tauopathy, namely 
Pick’s disease. Filamentous neuronal and glial 
hyperphosphorylated tau are the defining 
neuropathological characteristics associated 
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with Pick’s disease [6]. Pick’s disease is 
associated with severe neuronal and glial loss 
leading to frontotemporal lobe atrophy [6]. 
Pathologically, a key feature of Pick’s disease 
is the presence of Pick bodies representing 
intracellular inclusions containing aggregates 
of hyperphosphorylated tau [7]. Previous 
studies have identified the presence of TDP-43 
inclusions in Pick’s disease [8, 9].  
 
In the present study, application of our site-
directed caspase-cleavage antibody to TDP-43 
revealed labeling that was more or less 
restricted to CA1 region of the hippocampus in 
Pick’s disease. Intense labeling within Hirano 
bodies and reactive astrocytes was similar to 
what we observed previously in AD [5]. 
Roughly, 21% of the total number of Pick 
bodies identified within area CA1 contained 
caspase-cleaved TDP-43. These results 
suggest the presence of modified TDP-43 is a 
consistent finding in tauopathies including AD 
and Pick’s disease, however, given the relative 
paucity of caspase-cleaved TDP-43 labeling 
within Pick bodies, inclusions of TDP-43 may 
not be a causative factor in Pick body 
formation. 
 
Materials and Methods 
 
Materials 
 
The mouse TauC3 antibody (caspase-cleaved 
tau antibody) was purchased from Invitrogen/ 
Chemicon (Carlsbad, CA). The caspase-
cleavage product antibody to TDP-43 (TDPccp) 
was an in house antibody synthesized based 
upon a putative caspase cleavage consensus 
site (DVMD219) within TDP-43. This antibody 
has previously been shown to be a specific 
marker for caspase-cleaved TDP-43 [5]. PHF-1 
was a generous gift from Dr. Peter Davies 
(Albert Einstein College of Medicine, Bronx, 
NY). 
Human subjects 
 
Autopsy brain tissue from five neuropatholo-
gically confirmed Pick’s cases was studied. 
Case demographics are presented in Table 1. 
Human brain tissues used in this study was 
provided by the Institute for Brain Aging and 
Dementia Tissue Repositories at the University 
of California, Irvine. 
 
Immunohistochemistry and 
immunofluorescence microscopy 
 
Free-floating 40 μm-thick serial sections were 
used for immunohistochemical and 
immunofluorescence studies as previously 
described [10]. Antibody dilutions were the 
following: TDPccp (1:100), PHF-1 (1:500), and 
mAb TauC3 (1:100). Antigen visualization was 
determined using ABC complex (ABC Elite 
immunoperoxidase kit, Vector labs), followed 
by brown/red DAB substrate (Vector Labs) for 
single labeling. Visualization of bright-field 
double label immunohistochemistry was 
accomplished using brown DAB for one label 
and blue SG substrate (Vector Labs) for the 
second label. For immunofluorescence co-
localization studies, antigen visualization was 
accomplished using an Alexa fluor 488-labeled 
tyramide (green, Ex/Em = 495/519) for one 
label and streptavidin Alexa Fluor 555 (red, 
Ex/Em = 555/565) for the second label, both 
from Invitrogen (Carlsbad, CA). 
 
Quantification and statistical analysis 
 
A semi-quantitative analysis was performed by 
first taking 20X immunofluorescence, 
overlapping images from three different fields 
in area CA1 of the hippocampus in three 
separate Pick’s cases. Photographs were then 
analyzed by counting the number of inclusion 
bodies per field for each case. Data were than 
averaged ±S.E.M. Additionally, PHF-1 labeling 
Table 1. Case Demographics 
Case  Group  Sex  Age  PMI (hrs)  BraakNFT  MMSE  
1  Pick  M  66  5.0  3  0  
2  Pick  M  72  2.5  0  N/A  
3  Pick  F  76  3.3  0  5  
4  Pick  F  68  3.2  0  N/A  
5  Pick  F  70  3.5  N/A  N/A  
Note. PMI, postmortem interval; MMSE, mini mental state examination; N/A, not available 
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was utilized as a general marker for Pick 
bodies and compared with the number of PHF-
1-labeled Pick bodies that co-localized with 
either TauC3 or TDPccp. Data are 
representative of the average number of 
TDPccp or TauC3 Pick bodies co-localized with 
PHF-1 in each 20X field (3 fields total for 3 
different cases). In a parallel experiment, we 
also determined the percent of Pick bodies 
that were identified as having both TDPccp 
and TauC3 present. For determining statistical 
differences, the degree of colocalization of 
PHF-TDPccp and PHF-TauC3 double-labeled 
Pick Bodies were analyzed by Kruskal-Wallis 
nonparametric alternative test for a 1-way 
ANOVA with statistical significance established 
at a p-value < 0.05. All calculations were 
performed using a SAS program version 9.1.3 
Service Pack 3 for Windows XP-Pro. 
 
Results and Discussion 
 
Recent advances have suggested that in TDP-
43 proteinopathies including FTLD-U and ALS, 
a key event that may promote disease 
progression is the redistribution of TDP-43 
from the nucleus to the cytoplasm [11]. In 
addition, brain samples from both FTLD-U and 
ALS are enriched in smaller (~25 kDa) 
phosphorylated fragments of TDP-43, 
suggesting that posttranslational modification 
of TDP-43 may signal  a shift  to a  toxic gain of  
Figure 1. Caspase-cleaved TDP-43 in Pick’s disease. A and B: Representative single labeling from a Pick’s 
case utilizing the TDPccp antibody illustrating staining in the CA1 region of the hippocampus within Pick 
bodies (arrowheads, A and B), Hirano bodies (arrow, A) and astrocytes (arrows, B). C and D: Representative 
double-labeling from a Pick’s case employing TDPccp antibody and PHF-1 within the substantia nigra (C) and 
amygdala (D). A sparse number of Pick bodies was detected in both brain regions, and in some cases co-
localized with PHF-1 (arrows, C and D). All scale bars represent 10 μm. 
TDP43 and Pick’s disease  
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Figure 2. Caspase-cleaved TDP-43 labeling within the hippocampus of Pick’s disease is uniform and regionally 
defined. A-D: Representative immunofluorescence double-labeling utilizing the TDPccp antibody (green) and 
PHF-1 (red) revealed the presence of caspase-cleaved TDP-43 within Pick (arrows, A) and Hirano bodies 
(arrowhead, B) predominantly within area CA1 (A and B), but not within granule cells of the dentate gyrus (C). 
PHF-1 labeling was evident throughout all areas of the hippocampus and widespread within the dentate gyrus 
(D). A small percentage of Pick bodies were co-localized with both antibodies (arrows, A and B). E and F: 
Representative immunofluorescence double-labeling within the CA1 region of the hippocampus in Pick’s 
disease utilizing TauC3 (green) and PHF-1 (red). Unlike TDPccp, which appeared to reveal a more uniform 
staining pattern, TauC3 staining was localized centrally within Pick bodies and displayed a more aggregated 
appearance. Scale bars are 10 μm in A, B, and F, 100 μm in C and D, and 20 μm in E. 
TDP43 and Pick’s disease  
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function [12]. One candidate protease that 
may be involved in the proteolytic processing 
of TDP-43 is caspase-3. Zhang et al. have 
shown that TDP-43 is a substrate for caspase-
3 leading to the generation of 25 and 35 kDa 
species [2]. Further, utilizing an in vitro 
model, the authors demonstrated a 
caspase-dependent cleavage and 
redistribution of TDP-43 from its 
nuclear localization to the cytoplasm 
[2]. Our lab has also supported the 
hypothesis that caspases may play a 
major role in the processing of TDP-43 
in the AD brain: utilizing a site-directed 
caspase-cleavage antibody to a known 
consensus cleavage site within TDP-43 
(DVMD219), we showed strong 
immunoreactivity within plaque regions, 
tangles, reactive astrocytes and Hirano 
bodies of the hippocampus [5]. To 
confirm and extend these findings, we 
examined whether caspase-cleaved 
TDP-43 is a finding in the Pick’s 
disease. Like AD, Pick’s disease is 
classified as a tauopathy characterized 
pathologically by the presence of round 
Pick body structures containing 
predominantly hyperphosphorylated, 
aggregated tau [13]. 
 
Five confirmed cases of Pick’s disease 
(Table I) were examined by 
immunohistochemistry utilizing our 
caspase-cleaved antibody to TDP-43, 
termed TDPccp. As an initial approach, 
immunoreactivity to TDPccp was 
assessed in three different brain 
regions including the hippocampus, 
amygdala, and substantia nigra. As 
depicted in Figure 1, we detected 
labeling of TDPccp within numerous 
Pick bodies in the hippocampus (Figure 
1A and B) as well as within the 
substantia nigra and amygdala 
although in the latter case in much 
fewer numbers (Figure 1C and D). The 
localization of TDPccp within Pick 
bodies in the substantia nigra and 
amygdala was confirmed following 
double-labeling with PHF-1, a general 
marker for Pick bodies (arrows, Figure 
1C and D). In addition to Pick body 
labeling, staining of TDPccp in the 
hippocampus was also observed in 
Hirano bodies (arrow, Figure 1A) and 
reactive astrocytes (arrows, Figure 1B). 
 
The staining of TDPccp within Hirano bodies 
was similar to what we previously observed in 
AD, being largely confined to area CA1 of the 
hippocampus [5]. Hirano bodies are rod-
Figure 3. Quantification of Pick bodies double-labeled by TDPccp, 
TauC3, and PHF-1. In both A and B, PHF-1 labeling was utilized 
as a marker for Pick bodies. A: Data show the average number of 
Hirano bodies labeled with TDPccp, Pick bodies labeled with PHF-
1, and Pick bodies with both PHF-1 and TDPccp, identified in a 
20X field of area CA1 (n=3 fields for 3 different Pick disease 
cases) ±S.E.M. B: a semi-quantitative analysis was performed to 
estimate the total number of PHF-1-labeled Pick bodies that co-
localized with either TDPccp or TauC3 within the CA1 region of 
the hippocampus (percent given above bars). Results indicated 
the total number of double-labeled Pick bodies with caspase-
cleaved tau plus phosphorylation was significantly greater 
compared with caspase-cleaved TDP-43 plus phosphorylation. 
Data represent the average (±S.E.M.) of three different fields 
from three representative Pick cases (2 = 3.857, p-value* < 
0.05). 
TDP43 and Pick’s disease  
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shaped, cytoplasmic inclusions that are found 
predominantly within the hippocampus in a 
variety of neurodegenerative diseases, 
including AD and Pick’s disease [14]. The 
function of Hirano bodies is unknown as is 
whether the presence of these structures 
contributes to observed neurodegeneration in 
various neurodegenerative disorders. Thus, 
the finding of caspase-cleaved TDP-43 within 
Hirano bodies of the AD and Pick’s disease 
brain suggest this might be a common feature 
of tauopathies. 
 
To examine the relative and regional 
distribution of TDPccp labeling within the 
hippocampus, double-label immunofluore-
scence studies were carried out utilizing PHF-1 
as a general marker for Pick bodies. Co-
localization of both antibodies was evident 
within Pick bodies in area CA1 and the staining 
pattern revealed a homogenous, uniform 
labeling for TDPccp (arrows, Figure 2A). 
Interesting, although double-labeling within 
Pick bodies was observed, Hirano bodies were 
labeled only with TDPccp (arrowhead, Fig. 2B). 
Numerous Pick bodies identified by PHF-1 
staining were evident within the granule cell 
layer of the dentate gyrus (Figure 2D). 
However, there was a complete lack of 
labeling with TDPccp in the same area (Figure 
2C), indicating that caspase-cleaved TDP-43 is 
regionally restricted to Pick and Hirano bodies 
within the CA1 region of the hippocampus. A 
semi-quantitative analysis indicated that 
approximately 21% of the total number of Pick 
bodies identified following labeling with PHF-1 
contained caspase-cleaved TDP-43 (Figure 3). 
 
To determine whether other known substrates 
for caspase cleavage are present within Pick 
bodies, experiments were undertaken using an 
antibody that specifically detects caspase-
cleaved tau (TauC3) [15]. In a previous study, 
it was shown that a large fraction of Pick 
bodies (~90%) were double-labeled with both 
PHF-1 and TauC3 [16]. Confirming these 
findings, in the present study co-localization of 
PHF-1 and TauC3 was evident within Pick 
Figure 4. Caspase-cleaved tau and TDP-43 co-localization within Pick bodies. A and B: Representative 
immunofluorescence double-labeling employing the TDPccp antibody (green) and TauC3 (red) in CA1. Panel A 
also displays nuclear staining using Hoest (blue). Note the relative uniform distribution of TDPccp while TauC3 
appeared to be less uniform and in some cases more centrally distributed within the Pick body (B). Co-
localization was also observed occasionally within Hirano bodies (A). C-D: Identical to Panels A and B showing 
TauC3 labeling (red, C), TDPccp (green, D), and the overlapped image for both markers (yellow, E). Scale bars 
represent 10 μm. 
TDP43 and Pick’s disease  
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bodies in the hippocampus (Figure 2E and F). 
In general, the staining pattern was different 
than what was observed for TDPccp: TauC3 
labeling was centrally located within the Pick 
body and displayed an aggregated, fibrillar 
pattern of staining (Figure 2F). In addition, a 
much larger fraction of Pick bodies were 
double-labeled for PHF-1 and TauC3 (79%) in 
comparison to TDPccp (21%) (Figure 3). Taken 
together, these results suggest the caspase-
cleavage of tau may promote its ability to 
aggregate, an observation that has been 
identified as a putative mechanism for tangle 
formation in the AD brain [15, 17]. Moreover, 
because a much larger fraction of Pick bodies 
are TauC3-positive, this supports the idea that 
the caspase cleavage of tau may be an 
important event in the formation and evolution 
of Pick bodies. 
 
In a final set of experiments, we evaluated 
whether co-localization of TauC3 and TDPccp 
was evident in Pick bodies of the 
hippocampus. As shown in Figure 4, double-
labeling of these antibodies was evident within 
both Pick and Hirano bodies. Similar to what 
was observed previously, TauC3 labeling was 
non-uniform in appearance, and was centrally 
located within Pick body structures (Fig. 4A 
and B). A semi-quantitative analysis revealed 
that approximately 46% ±13% of identified 
Pick bodies contained both caspase-cleaved 
tau and TDP-43, with the remaining 54% of 
Pick bodies appeared to be single-labeled with 
only TauC3. 
 
In conclusion, we have demonstrated the 
presence of caspase-cleaved TDP-43 within 
Pick and Hirano bodies of the Pick’s disease 
brain. These findings support the conclusion 
that the presence of TDP-43 pathology is not 
solely restricted to TDP-43 proteinopathies, 
but may be more widely distributed in a 
number of neurodegenerative diseases 
including tauopathies. 
 
The presence of caspase-cleaved TDP-43 
within Hirano bodies is similar to our previous 
findings in AD, and suggests that this may be a 
common finding in various tauopathies. 
Further studies will be necessary to elucidate 
the relationship between TDP-43 and the 
formation and evolution of Hirano bodies. 
Previous studies have demonstrated that 
Hirano bodies are rich in cytoskeletal proteins 
including actin and tau [18, 19]. Further, a 
previous study by Wang et al., indicated the 
presence of TDP-43 within the 
somatodendrites of hippocampal neurons 
where it co-localized with beta-actin mRNA 
[20]. Based on these findings it is interesting 
to speculate on a role of TDP-43 in the 
regulation of the cytoskeleton, a role that may 
be disrupted following the activation of 
caspases and cleavage of TDP-43 in various 
neurodegenerative disorders including AD and 
Pick’s disease. 
 
Another finding of the present study was the 
presence of TauC3 and TDPccp within Pick 
bodies in the hippocampus of affected 
patients. Our data clearly demonstrated a 
staining pattern for TauC3 that was fibrillar in 
appearance, and supports previous studies 
that the caspase cleavage of tau may promote 
the ability of tau to aggregate into beta-sheet 
structures [15, 17]. Whether the caspase-
cleavage of tau promotes Pick body formation 
in Pick’s disease is unknown, but based upon 
the large fraction of Pick bodies containing 
caspase-cleaved tau, it is suggested that this 
may be an important event underlying the 
formation of these pathological inclusions. 
Additional studies are warranted to assess the 
role of caspase activation and cleavage of 
tau/TDP-43 in Pick/Hirano body formation. 
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